Hydroxychloroquine sales spiked almost 100% in Australia at start of Covid pandemic, study finds
There was also a rise in prescriptions for ivermectin being filled, despite no evidence either drug is effective against the virusThe amount of hydroxychloroquine and ivermectin dispensed from Australian pharmacies increased significantly in 2020 as the Covid pandemic took hold, according to new research.Analysis of six publicly subsidised drugs – including hydroxychloroquine, ivermectin, corticosteroids and the common antibiotic azithromycin – found Covid-related changes in prescription patterns in Australia.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 30, 2021 Category: Science Authors: Donna Lu Tags: Health Coronavirus Drugs Medical research Australia news Source Type: news

Common antibiotic is NOT effective at preventing symptoms of COVID-19 in patients with mild casesĀ 
Five COVID-19 patients being treated with azithromycin were hospitalized compared to no patients in the placebo group, a new study from the University of California, San Francisco found. (Source: the Mail online | Health)
Source: the Mail online | Health - July 19, 2021 Category: Consumer Health News Source Type: news

Azithromycin no more effective against COVID-19 than placebo: Study
The research, published in the Journal of the American Medical Association, included 263 participants who all tested positive for SARS-CoV-2, the virus which causes COVID-19, within seven days before entering the study. (Source: The Economic Times)
Source: The Economic Times - July 19, 2021 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191], (updated 3rd June 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily 3 June 2021 new recommendations on azithromycin to treat COVID-19 added (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 16, 2021 Category: Consumer Health News Source Type: news

Common COVID-19 antibiotic no more effective than placebo
(University of California - San Francisco) A UC San Francisco study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 16, 2021 Category: Infectious Diseases Source Type: news

Covid first wave led to increase in antibiotic misuse in India: Study
The researchers at Washington University in the US estimated that Covid-19 likely contributed to 216.4 million excess doses of antibiotics and 38 million more doses of azithromycin in adults from June 2020 through September 2020, a period of peak Covid-19 activity in India. (Source: The Economic Times)
Source: The Economic Times - July 2, 2021 Category: Consumer Health News Source Type: news

Doxycycline Trumps Azithromycin for Asymptomatic Rectal Chlamydia Doxycycline Trumps Azithromycin for Asymptomatic Rectal Chlamydia
A 1-week course of doxycycline proved to be better than single-dose azithromycin.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 30, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

What Types of New Therapies are Available for Cystic Fibrosis?
Discussion Cystic fibrosis (CF) was identified in 1938 by Dr. Dorothy Andersen who described 49 patients with pancreatic insufficiency. Since that time significant achievements in the knowledge about the disease and treatments for patients have changed the mortality from a few months to patients living into middle adulthood or even later. Quality of life for patients and their families and friends has also markedly improved. CF is the classic Mendelian autosomal recessive genetic disorder which is a worldwide disorder but affects people of north European ancestry more often where the main mutation is more common. There are...
Source: PediatricEducation.org - June 28, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Most drugs for treating adult Covid patients not recommended for kids: Government guidelines
About the treatment of children, the guidelines by the Union Health Ministry said most drugs used in adults such as ivermectin, hydroxychloroquine, favipiravir and antibiotics such as doxycycline or azithromycin have not been tested on children for prevention or treatment of Covid infection among them. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 16, 2021 Category: Pharmaceuticals Source Type: news

Managing COVID-19 [NG191], NICE (updated 3rd June 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily. On 3 June 2021 we added new recommendations on azithromycin to treat COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 3, 2021 Category: Consumer Health News Source Type: news

COVID-19 Prolongs QT Interval Independent of Other Factors COVID-19 Prolongs QT Interval Independent of Other Factors
COVID-19 infection can prolong corrected QTc in hospitalized patients, even in the absence of hydroxychloroquine and azithromycin treatment.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 26, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial , The Lancet
Findings from the PRINCIPLE platform trial show azithromycin did not improve in median time to self-reported recovery (estimated benefit 0.94 days; 95% Bayesian credibility interval −0.56 to 2.43) in this population, when compared to usual care ± other interventions. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 8, 2021 Category: Consumer Health News Source Type: news

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
RCT (7,763 included in the assessment of azithromycin) found no significant difference for 10 days of azithromycin vs usual care for mortality at 28 days (22% for both, p=0.50), hospital stay (10 days vs 11 days) or the proportion discharged alive at 28 days (RR 1.04, p=0.19). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 4, 2021 Category: Consumer Health News Source Type: news

COVID-19 Therapeutic Alert - Antimicrobials (azithromycin and doxycycline) Not Beneficial in the Management of COVID-19 (SARS-CoV-2) Positive Patients, MHRA
Azithromycin and doxycycline should NOT be used in the management of confirmed or suspected COVID-19 infection within primary care, and azithromycin should not be used in hospitalised patients, unless there are additional indications for which use remains appropriate. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 1, 2021 Category: Consumer Health News Source Type: news

PRINCIPLE trial finds no benefit from antibiotics, azithromycin and doxycycline for COVID-19 patients, NIHR
A NIHR-supported study investigating potential COVID-19 treatments that might be suitable for patients in the community has found that the commonly used antibiotics, azithromycin and doxycycline, do not reduce recovery time for patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 25, 2021 Category: Consumer Health News Source Type: news

Super gonorrhea could be fueled by antibiotic use amid the pandemic
A WHO spokesperson told The Sun that the use of azithromycin in misguided attempts to treat coronavirus may be encouraging the STI to become resistant to the common antibiotic. (Source: the Mail online | Health)
Source: the Mail online | Health - December 29, 2020 Category: Consumer Health News Source Type: news

Drug treatments for covid-19: living systematic review and network meta-analysis (update), BMJ
Updated review includes results for new interventions (azithromycin, colchicine, interferons, rhG-CSF, tocilizumab) and evidence remdesivir may not reduce mortality or time to symptom resolution; glucocorticoids probably reduce length of ICU stay and increase ventilator-free days BMJ2020; 370 doi: 2 External 0 0 0 https://doi.org/10.1136/bmj.m2980 false https://doi.org/10.1136/bmj.m2980 true false%> (Published 30 July 2020). Cite this as: BMJ 2020;370:m2980. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 21, 2020 Category: Consumer Health News Source Type: news

CAS alert: Azithromycin in the Management of COVID-19 Positive Patients
It is now recommended that azithromycin should NOT be used in the managementof confirmed or suspected COVID-19 infection in hospitalised patients unless there are additional indications for which its (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 17, 2020 Category: Drugs & Pharmacology Source Type: news

COVID-19 Therapeutic Alert: Azithromycin in the Management of COVID-19 (SARS-CoV-2) Positive Patients, DHSC
RECOVERY trial showed no significant clinical benefit of either oral or IV azithromycin in patients hospitalised with COVID-19. It is now recommended azithromycin should NOT be used in this population unless there are additional indications for which its use remains appropriate. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 16, 2020 Category: Consumer Health News Source Type: news

Trial of Azithromycin in Severe COVID-19 Patients Finds No Benefit Trial of Azithromycin in Severe COVID-19 Patients Finds No Benefit
A clinical trial of the widely-used antibiotic azithromycin in COVID-19 patients in hospital has found no convincing evidence of benefit, prompting doctors to announce on Monday that they have closed that section of the trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 15, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Vaginal Cleansing Protocol Curbs Deep SSIs After Cesarean Vaginal Cleansing Protocol Curbs Deep SSIs After Cesarean
' We aimed to decrease our SSI rate by 30% by adopting an intervention of cleansing followed by azithromycin,'Dr Johanna Quist-Nelson said, presenting at the ACOG 2020 virtual meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2020 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Mechanism of action of chloroquine/hydroxychloroquine for COVID-19 infection
(Bentham Science Publishers) The recent serious outbreak of Covid19 has required urgent medical treatments for numerous patients. No clinically active vaccines or antiviral agents are available for Covid19. According to several studies, Chloroquine (CQ) and Hydroxychloroquine (HCQ) have shown promises as Covid19 antiviral especially when administered with Azithromycin (AZM). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 30, 2020 Category: Infectious Diseases Source Type: news

General practice asked to help identify potential participants for study evaluating early community treatment for Covid-19, Trials
The PRINCIPLE study is currently evaluating azithromycin and doxycycline added to usual care. People with symptomatic Covid-19 may be eligible if they are over 65 or over 50 with an underlying health condition. People can register and participate in the trial entirely remotely. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 27, 2020 Category: Consumer Health News Source Type: news

Some Patients Have Increase in Cardiac Events With Azithromycin
Risk for cardiac events higher with azithromycin versus amoxicillin in those using QT - prolonging drugs (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 8, 2020 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Infections, Internal Medicine, Critical Care, Emergency Medicine, Pharmacy, Pulmonology, Journal, Source Type: news

Some Patients Have Increase in Cardiac Events With Azithromycin
THURSDAY, Oct. 8, 2020 -- Patients using QT-prolonging drugs have an increased risk for cardiac events in association with azithromycin versus amoxicillin, according to a study published online Sept. 15 in JAMA Network Open. Haridarshan Patel,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 8, 2020 Category: Pharmaceuticals Source Type: news

Lopinavirritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
Summary Background Lopinavir –ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19. M ethods In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either u...
Source: Current Awareness Service for Health (CASH) - October 6, 2020 Category: Consumer Health News Source Type: news

Potential COVID Drug May Raise Heart Risk: Study
The widely prescribed antibiotic azithromycin is being investigated as a COVID-19 treatment, but a new study warns it could increase the risk of heart problems. (Source: WebMD Health)
Source: WebMD Health - September 21, 2020 Category: Consumer Health News Source Type: news

Potential COVID-19 Drug Could Increase Heart Risk: Study
MONDAY, Sept. 21, 2020 -- The widely prescribed antibiotic azithromycin is being investigated as a COVID-19 treatment, but a new study warns it could increase the risk of heart problems. Researchers analyzed data from millions of patients (average... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 21, 2020 Category: General Medicine Source Type: news

Potential COVID-19 drug azithromycin may increase risk for cardiac events
(University of Illinois at Chicago) Azithromycin -- a commonly-prescribed antibiotic -- also is being investigated as a potential treatment for COVID-19. Researchers have found that azithromycin by itself is not associated with an increase in cardiac events; however, if the drug is taken with certain other drugs that affect the electrical functioning of the heart, then cardiac events increased. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2020 Category: International Medicine & Public Health Source Type: news

Azithromycin Fails to Help Hospitalized COVID-19 Patients Azithromycin Fails to Help Hospitalized COVID-19 Patients
The antibiotic azithromycin did not appear to provide any benefit to hospitalized COVID-19 patients who were having trouble breathing, according to a study in Brazil.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 14, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

More about chloroquine and hydroxychloroquine, CEBM (updated 30th August 2020)
VERDICT The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - September 2, 2020 Category: Consumer Health News Source Type: news

Hydroxychloroquine plus azithromycin increases heart risk, finds global study
(Columbia University Irving Medical Center) In the largest observational study of hydroxychloroquine and azithromycin, the drug combination has been linked to significant cardiovascular risks, including death. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 25, 2020 Category: International Medicine & Public Health Source Type: news

Hydroxychloroquine works in high-risk patients, and saying otherwise is dangerous
(Natural News) As of Wednesday, some 165,000 people in the United States have died from COVID-19. I have made the case in the American Journal of Epidemiology and in Newsweek that people who have a medical need to be treated can be treated early and successfully with hydroxychloroquine, zinc, and antibiotics such as azithromycin or doxycycline. I have also argued that these... (Source: NaturalNews.com)
Source: NaturalNews.com - August 14, 2020 Category: Consumer Health News Source Type: news

' Doubling Down' on Hydroxychloroquine QT Prolongation in COVID-19'Doubling Down' on Hydroxychloroquine QT Prolongation in COVID-19
Patients had progressively longer QT intervals with hydroxychloroquine plus azithromycin but also frequently received other drugs that had QT-prolonging effects in a new study.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 7, 2020 Category: Neurology Tags: Cardiology News Source Type: news

Study shows triple treatment including hydroxychloroquine and zinc leads to fewer hospitalizations
(Natural News) A new study shows that hospitalizations for coronavirus patients could be reduced by five times with the early use of zinc, azithromycin and a low dose of hydroxychloroquine. This is according to research led by Dr. Vladimir Zelenko, a primary care physician in New York, in collaboration with a pair of German doctors.... (Source: NaturalNews.com)
Source: NaturalNews.com - July 23, 2020 Category: Consumer Health News Source Type: news

February to March 2020 Saw Surge in Hydroxychloroquine Rx
WEDNESDAY, July 8, 2020 -- From February to March 2020, there was a considerable increase in the number of patients receiving outpatient prescriptions for hydroxychloroquine, chloroquine, and azithromycin, according to a research letter published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 8, 2020 Category: Pharmaceuticals Source Type: news

US hydroxychloroquine, chloroquine, azithromycin outpatient prescriptions October 2019-March 2020
(JAMA Network) How the prescription of hydroxychloroquine and chloroquine to outpatients has changed in the United States during the COVID-19 pandemic is examined in this study. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 6, 2020 Category: International Medicine & Public Health Source Type: news

Study: Azithromycin doubles risk for cardiovascular death versus amoxicillin
People who take the commonly prescribed antibiotic azithromycin were nearly twice as likely to die from a heart attack, stroke or other cardiovascular event than users of amoxicillin, a study found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 18, 2020 Category: Consumer Health News Source Type: news

CVD, Non-CVD Mortality Increased With Azithromycin Use
WEDNESDAY, June 17, 2020 -- Outpatient azithromycin use is associated with an increased risk for cardiovascular and noncardiovascular mortality, according to a study published online June 17 in JAMA Network Open. Jonathan G. Zaroff, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 17, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 news from Annals of Internal Medicine
(American College of Physicians) Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2020 Category: International Medicine & Public Health Source Type: news

U.K. Researchers Say They Have Found First Drug that Improves COVID-19 Survival
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients. Results were announced Tuesday and researchers said they would publish them soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care. The drug was given either orally or through an IV. It reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did ...
Source: TIME: Science - June 16, 2020 Category: Science Authors: MARILYNN MARCHIONE /AP Tags: Uncategorized Source Type: news

More evidence of no survival benefit in COVID-19 patients receiving hydroxychloroquine
(Cell Press) A study of electronic medical records from US Veterans Health Administration medical centers has found that hydroxychloroquine -- with or without azithromycin -- did not reduce the risk of ventilation or death and was associated with longer length of hospital stay. This analysis, published June 5 in the journal Med, is the first in the US to report data on hydroxychloroquine outcomes for COVID-19 from a nationwide integrated health system. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 5, 2020 Category: Infectious Diseases Source Type: news

First do no harm -- researchers urge halt in prescribing hydroxycholoroquine for COVID-19
(Florida Atlantic University) Researchers urge a moratorium on prescribing chloroquine or hydroxychloroquine, with or without azithromycin, to treat or prevent COVID-19, and caution that the reassuring safety profile of hydroxychloroquine may be more apparent than real. Safety data derive from decades of prescriptions by clinicians, primarily for their patients with lupus and rheumatoid arthritis, both of which are of greater prevalence in younger and middle age women, who are at very low risk of fatal heart outcomes due to hydroxychloroquine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 3, 2020 Category: Infectious Diseases Source Type: news

More about chloroquine and hydroxychloroquine, CEBM
VERDICT: The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - June 1, 2020 Category: Consumer Health News Source Type: news

CV Toxicity Tied to Azithromycin and/or Hydroxychloroquine
THURSDAY, May 28, 2020 -- Hydroxychloroquine and azithromycin may have a serious adverse impact on the cardiovascular system, according to a research letter published online May 22 in Circulation. Lee S. Nguyen, M.D., from Sorbonne... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 28, 2020 Category: Pharmaceuticals Source Type: news

Cancer Progression Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis
Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2020 Category: Cancer & Oncology Authors: Ryan McDonald Source Type: news

Hydroxychloroquine-azithromycin combo may be potentially lethal: Study
Hydroxychloroquine and azithromycin, alone or in combination, have been proposed for treatment of COVID-19 patients, the researchers said. They explained that reports of potentially lethal acute cardiac proarrhythmogenic effects -- promoting irregular heart rhythms -- have been described mainly with azithromycin but also with hydroxychloroquine. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 25, 2020 Category: Pharmaceuticals Source Type: news